{"brief_title": "A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine", "brief_summary": "To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).", "detailed_description": "Patients are randomized to one of three treatment regimens: ddC alone, Ro 31-8959 alone, and ddC plus Ro 31-8959. Treatment continues for at least 48 weeks. Patients are stratified by baseline CD4 count. (Per 09/26/94 amendment, a fourth arm, lower dose Ro 31-8959 plus ddC, was discontinued.)", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Saquinavir", "Zalcitabine"], "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - G-CSF and erythropoietin. - Prophylaxis or chronic suppression/maintenance therapy with dapsone, aerosolized pentamidine, isoniazid, rifampin, fluoroquinolones, pyrazinamide, ethambutol, fluconazole, itraconazole, acyclovir, clotrimazole, nystatin, trimethoprim/sulfamethoxazole, pyrimethamine, folic acid, sulfadiazine, clindamycin, and fansidar. Concurrent Treatment: Allowed: - Limited localized radiation therapy to the skin. Patients must have: - Documented HIV infection. - CD4 count 50 - 300 cells/mm3. - Received prior AZT that has been discontinued at least 28 days prior to study entry. - No active opportunistic infection requiring immediate treatment. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Signs or symptoms of peripheral neuropathy. - Malabsorption or inadequate oral intake (defined as unable to eat one or more meals daily because of chronic nausea, emesis, or abdominal/oral-esophageal discomfort. - Malignancy, visceral Kaposi's sarcoma, or lymphoma requiring systemic chemotherapy and/or radiotherapy within the next 48 weeks. - Any grade 3 or worse laboratory or clinical abnormality. - Inability to comply with protocol requirements. Concurrent Medication: Excluded: - Other antiretroviral drugs. - Experimental drugs. - Nephrotoxic or hepatotoxic drugs. - Drugs likely to cause peripheral neuropathy. - Antineoplastic agents. - Biologic response modifiers. Concurrent Treatment: Excluded: - Radiation therapy other than limited localized therapy to skin. Patients with the following prior conditions are excluded: - History of non-Hodgkin's lymphoma. - Unexplained fever >= 38.5 C (101.5 F) persisting for 14 days or longer within the 28 days prior to study entry. - Unexplained, chronic diarrhea (defined as 3 or more loose stools daily) persisting for 14 days or longer within the 28 days prior to study entry. - History of grade 2 or worse peripheral neuropathy. Prior Medication: Excluded: - Prior HIV proteinase inhibitor. - Prior antiretroviral therapy other than AZT. - Acute therapy for opportunistic infection within 14 days prior to study entry. Prior Treatment: Excluded: - More than 3 units of blood in any 21-day period within 3 months prior to study entry. Required: - Prior AZT.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "HIV Protease Inhibitors", "mesh_term": ["Infection", "Communicable Diseases", "HIV Infections", "Acquired Immunodeficiency Syndrome", "Zidovudine", "Zalcitabine", "Saquinavir"], "id": "NCT00002333"}